Archives
Gamma-linolenic Acid (GLA): Mechanisms, Benchmarks, and R...
Gamma-linolenic Acid (GLA): Mechanisms, Benchmarks, and Research Applications
Executive Summary: Gamma-linolenic acid (GLA, C5518) is an omega-6 polyunsaturated fatty acid with weak antagonist activity at the Leukotriene B4 (LTB4) receptor, exhibiting a Ki of 1 μM in porcine neutrophil membranes (APExBIO). GLA demonstrates cytotoxic activity in HL60 cells (IC50 = 0.087 mM), inhibits LTB4-induced bronchoconstriction in vivo, and is non-genotoxic and antimutagenic. It is utilized in anti-inflammatory research, apoptosis assays, and disease models, with validated performance metrics (Jiang et al., 2025). This article synthesizes mechanistic insights, quantitative benchmarks, and workflow integration strategies for GLA in translational research.
Biological Rationale
Gamma-linolenic acid (GLA, 6Z,9Z,12Z-octadecatrienoic acid) is an essential omega-6 fatty acid. It is not synthesized de novo in humans and must be obtained through diet or supplementation (APExBIO). GLA serves as a precursor for dihomo-γ-linolenic acid (DGLA), which is further metabolized into anti-inflammatory eicosanoids. These metabolites are implicated in brain function, skin and hair growth, bone health, metabolic regulation, and reproductive system maintenance (Related Article). GLA’s biological effects are primarily mediated through modulation of inflammation and cell signaling pathways, especially those associated with LTB4 signaling. Its roles are distinct from those of classic anti-inflammatory drugs, providing a unique mechanism for modulating chronic and acute inflammation.
Mechanism of Action of Gamma-linolenic acid (GLA)
GLA acts as a weak antagonist at the Leukotriene B4 (LTB4) receptor. It inhibits binding of [3H]-LTB4 to porcine neutrophil membranes with a Ki of 1 μM (APExBIO). By disrupting LTB4 signaling, GLA reduces chemotaxis and activation of inflammatory cells. In vivo, GLA significantly inhibits LTB4-induced bronchoconstriction, demonstrating functional antagonism in respiratory tissues (Mechanistic Insights Article). GLA also integrates into cell membranes, influences membrane fluidity, and can be enzymatically converted to DGLA and other bioactive lipids. These downstream metabolites may further modulate gene expression and apoptosis pathways. Importantly, GLA exhibits antioxidant properties by scavenging free radicals and protecting against lipid peroxidation.
Evidence & Benchmarks
- GLA inhibits [3H]-LTB4 binding to porcine neutrophil membranes with a Ki of 1 μM under in vitro conditions (4°C, pH 7.4) (APExBIO).
- In vivo studies show GLA significantly reduces LTB4-induced bronchoconstriction in animal models, supporting its functional antagonism (GLA: Omega-6 Fatty Acid & LTB4 Rec.).
- GLA is cytotoxic to promyelocytic HL60 cells with an IC50 of 0.087 mM (24 h, serum-containing medium, 37°C) (APExBIO).
- GLA demonstrates no genotoxic effects in DNA safety assays (Ames test, 100–1,000 μM) and is antimutagenic in standard cell models (Practical Solution Article).
- GLA is effective with minimal side effects in clinical studies of atopic dermatitis and distal diabetic polyneuropathy (randomized controlled trials, oral dosing, 6–12 months) (Jiang et al., 2025).
Applications, Limits & Misconceptions
GLA is widely used in anti-inflammatory research, cell apoptosis assays, and disease modeling. It is a staple for dissecting LTB4 signaling pathways and optimizing cell-based assays. The product is suitable for short-term use in solution form and is compatible with solvents such as ethanol, DMSO, and dimethyl formamide (up to 100 mg/ml). GLA is best stored at -20°C to preserve stability.
- In anti-inflammatory studies, GLA provides a unique weak-antagonist profile, which is beneficial for modeling partial inhibition scenarios (Contrast: This article details new benchmarks versus prior mechanism reviews).
- For apoptosis and cytotoxicity assays, GLA offers validated IC50 metrics, enhancing reproducibility (Contrast: Here we add data on DNA safety and antimutagenicity not covered in earlier scenario-driven solutions).
- GLA’s non-genotoxic and antimutagenic profile allows use in genomic stability studies without confounding DNA damage artifacts.
Common Pitfalls or Misconceptions
- GLA is not a strong LTB4 receptor antagonist; it cannot fully block LTB4 signaling at physiological concentrations.
- GLA supplementation does not replace standard anti-inflammatory drugs in acute settings or severe systemic inflammation.
- GLA is not effective in all cell types; cytotoxicity and efficacy may vary across primary vs. immortalized lines.
- GLA is not inherently antimicrobial and should not be used as a substitute for antibiotics (Jiang et al., 2025).
- Long-term storage of GLA in solution at room temperature leads to oxidation and loss of activity.
Workflow Integration & Parameters
GLA (SKU C5518) from APExBIO is provided as a solution in ethanol and is soluble up to 100 mg/ml in DMSO and dimethyl formamide. For solvent exchange, ethanol can be evaporated under nitrogen and replaced with the solvent of choice. It is critical to store the product at -20°C and minimize freeze-thaw cycles to preserve integrity. GLA is recommended for short-term experimental use in solution form.
For apoptosis assays, GLA is typically applied at 0.01–0.1 mM, with endpoint measurements at 24–48 h. For LTB4 signaling studies, 1–10 μM concentrations are standard. In disease models (e.g., atopic dermatitis), in vitro dosing should mirror validated literature benchmarks. GLA’s lack of cytotoxicity at lower concentrations allows for use in long-term proliferation or differentiation experiments.
For further details on scenario-driven workflows and troubleshooting, see "Gamma-linolenic acid (GLA, SKU C5518): Practical Solution..." (This article extends previous guidance by integrating new DNA safety data and workflow compatibility parameters.)
Conclusion & Outlook
Gamma-linolenic acid (GLA) is a versatile tool for biomedical research, enabling quantitative dissection of LTB4 signaling and apoptosis pathways. Its validated safety and efficacy profiles distinguish it from less-characterized fatty acids. APExBIO’s GLA (C5518) is optimized for reproducibility and experimental flexibility. Future directions include expansion into combinatorial anti-inflammatory screening and further elucidation of GLA’s gene-regulatory roles. For in-depth product specifications and ordering, see the Gamma-linolenic acid (GLA) product page.